Collplant Biotechnologies Ltd.
4 Oppenheimer St.
Weizmann Science Park
Rehovot 7670104
Israel
January 6, 2023
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-7010
Re: | Collplant Biotechnologies Ltd. |
Registration Statement on Form F-3 | |
File No. 333-269087 |
VIA EDGAR
Ladies and Gentlemen:
Reference is made to the Registration Statement on Form F-3 (File No. 333-269087) filed by CollPlant Biotechnologies Ltd. on December 30, 2022 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933 (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated onto the cover page of the Registration Statement.
“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.”
If you have any questions or comments in connection with this delaying amendment, please contact Eyal Peled of Greenberg Traurig, LLP at (212) 801-9210.
Very truly yours, | ||
COLLPLANT BIOTECHNOLOGIES LTD. | ||
By: | /s/ Eran Rotem | |
Name: | Eran Rotem | |
Title: | Deputy CEO and Chief Financial Officer |